Prof. Xinhong Wu 吴新红
Chief Physician, Professor
Department of Breast Surgery, Hubei Cancer Hospital, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of breast diseases, minimally invasive breast tumor surgery, and breast cosmetic, reconstructive, and restoration procedures. Focuses on early breast cancer diagnosis and systematic standardized care, including surgery, neoadjuvant and postoperative adjuvant chemotherapy, prognosis assessment, and individualized therapy.
Dr. Wu holds a doctorate in surgery and serves as Chief Expert of the Breast Cancer MDT Team at Hubei Cancer Hospital and Director of the Hubei Breast Disease Prevention and Research Center. Dr. Wu has led or participated in eight national and provincial research projects, received one major Hubei scientific achievement award, co-edited Targeted Therapy for Cancer, and published over 30 academic papers.
Professional roles
- Standing Committee Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Committee Member, Breast Cancer Expert Committee, National Cancer Center
- Vice Chair, Oncology Branch, Wuhan Medical Association
- Chair, Breast Professional Committee, Hubei Anti-Cancer Association
Name order: in Chinese the family name comes first (Wu Xinhong). Papers usually list the name as Xinhong Wu or Wu X.
Selected publications
68 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Curr Med Chem, 2026 (senior author): Breast Cancer Therapy with Quantum Dots: NIR-II Image-Guided Interventions, Multimodal Treatment, and Translation. PubMed 42634365
- Transl Cancer Res, 2026 (senior author): Clinicopathological characteristics and prognosis of breast carcinoma with apocrine differentiation: a propensity score-matched analysis of the SEER database. PubMed 42591679
- Clin Proteomics, 2026 (senior author): Nipple aspirate fluid as a proximal breast liquid biopsy platform: advancing precision risk management in breast cancer. PubMed 42218386
- Biomedicines, 2026 (senior author): Research Progress of PROTACs in Breast Cancer: Subtype-Oriented Target Landscape, Clinical Stratification Evidence, and Engineering Strategies for Translation. PubMed 42072376
- Cancer Chemother Pharmacol, 2026 (senior author): Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. PubMed 41579215
- Discov Oncol, 2025 (senior author): Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights. PubMed 40721545
- J Cell Mol Med, 2025 (senior author): Single-Cell Transcriptome Analysis Uncovers La Ribonucleoprotein 6 (LARP6) as a Dual Regulator of Proliferation and Immune Infiltration in Triple-Negative Breast Cancer. PubMed 40635123
- BMC Cancer, 2025 (first author): Intraductal chemotherapy for triple-negative breast cancer: a pathway to minimally invasive clinical treatment. PubMed 39966717
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion